A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects ≥3 Months of Age With Atopic Dermatitis

Trial Profile

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects ≥3 Months of Age With Atopic Dermatitis

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs MSRD 100 (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merz Pharmaceuticals
  • Most Recent Events

    • 08 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 20 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top